Active Recombinant Cynomolgus Monkey TIGIT protein, Fc-tagged

• Cat.No.: TIGIT-197C
• Product Overview: Recombinant Cynomolgus Monkey TIGIT(Met22-Pro142) fused with Fc region of Human IgG1 at C-terminal was expressed in HEK293.

Specification

• Description: TIGIT (T cell Immunoreceptor with Ig and ITIM domains), also called VSTM3 (V-set and transmembrane domain-containing 3), VSIG9 (V-set and Ig domain-containing 9) and WUCAM (Washington University cell adhesion molecule) is a 30-34 kDa type I transmembrane protein that is a member of the CD28 family within the Ig superfamily of proteins. Human TIGIT cDNA encodes 244 amino acids (aa) including a 21 aa signal sequence, a 120 aa extracellular region with a V-type Ig-like domain and two potential N-glycosylation site, a 21 aa transmembrane sequence, and an 82 aa cytoplasmic domain with an ITIM motif. A 170 aa variant diverges after aa 166. Within the ECD, human TIGIT shares only 68-75% aa sequence identity with mouse, porcine, canine, equine and bovine TIGIT. Cyno TIGIT shares 88.4% homology with human TIGIT. TIGIT is expressed on NK cells and subsets of activated, memory and regulatory T cells, and particularly on follicular helper T cells within secondary lymphoid organs. It binds to CD155/PVR/Necl-5 and Nectin-2/CD112/PVRL2 that appear on dendritic cells (DC) and endothelium. Binding of TIGIT by DC induces IL-10 release and inhibits IL-12 production. Ligation of TIGIT on T cells down‑regulates TCR-mediated activation and subsequent proliferation, while NK cell TIGIT ligation blocks NK cell cytotoxicity. Through CD155 and Nectin-2, which also interact with DNAM-1/CD226 and CD96/Tactile, TIGIT is part of an interacting network of Ig superfamily members that may augment or oppose each other. In particular, TIGIT binding to CD155 can antagonize the effects of DNAM-1. Soluble TIGIT is able to compete with DNAM-1 for CD155 binding and attenuates T cell responses, while mice lacking TIGIT show increased T cell responses and susceptibility to autoimmune challenges.
• Source: HEK293
• Species: Cynomolgus Monkey
• Tag: Fc
• Predicted N Terminal: Met22
• Form: Lyophilized from a 0.2 μm filtered solution in NaH2PO4, NaCl and EDTA.
• Bio-activity: Measured by its binding ability in a functional ELISA. When Recombinant Human CD155/PVR is coated at 2.5 μg/mL (100 μL/well), the concentration of Recombinant Cynomolgus Monkey TIGIT Fc Chimera that produces 50% optimal binding response is 12-72 ng/mL.
• Molecular Mass: Predicted Molecular Mass: 40 kDa
  SDS-PAGE: 43 - 60 kDa, reducing conditions
• Endotoxin: <0.1 EU per 1 μg of the protein by the LAL method.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  12 months from date of receipt, -20 to -70 centigrade as supplied.
  1 month, 2 to 8 centigrade under sterile conditions after reconstitution.
  3 months, -20 to -70 centigrade under sterile conditions after reconstitution.
• Reconstitution: Reconstitute at 200 μg/mL in PBS.

Gene Information

• Gene Name: TIGIT T-cell immunoreceptor with Ig and ITIM domains [ Macaca fascicularis ]
• Official Symbol: TIGIT
• Synonyms: TIGIT; T-cell immunoreceptor with Ig and ITIM domains
• Gene ID: 102121588

Reviews

11/25/2022

With its well-characterized nature and availability in various formats, the TIGIT protein is an advantageous tool that aids researchers in achieving their scientific goals.

08/05/2017

Whether it's troubleshooting issues, optimizing experimental protocols, or providing detailed information about the protein, the manufacturer's support team is dedicated to helping researchers overcome any challenges they may encounter.

05/21/2017

The manufacturer also ensures that the TIGIT protein is well-characterized, with extensive documentation on its functional properties.

Q&As

In which types of cancers is TIGIT inhibition being investigated?

TIGIT inhibitors are being studied in a range of cancers, including lung cancer, breast cancer, and melanoma, among others.

How is TIGIT relevant in autoimmune diseases?

TIGIT is being explored as a potential target for treating autoimmune diseases by modulating immune responses to prevent excessive inflammation.

What clinical applications does TIGIT have in cancer therapy?

TIGIT is being explored as a potential target for cancer immunotherapy, with drugs designed to block TIGIT and enhance the immune system's ability to attack cancer cells.

How does TIGIT differ from other immune checkpoint proteins like PD-1 and CTLA-4?

TIGIT operates as an immune checkpoint, similar to PD-1 and CTLA-4, but it has distinct mechanisms of action and may regulate different aspects of the immune response.

Are there any potential side effects associated with TIGIT-targeted therapies?

As with any immunotherapy, potential side effects may include immune-related adverse events such as inflammation in various organs, but the specific profile is still under investigation.